Relapsing multiple sclerosis (RMS)

Active Ingredient: Daclizumab

Indication for Daclizumab

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Daclizumab is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) who have had an inadequate response to at least two disease modifying therapies (DMTs) and for whom treatment with any other DMT is contraindicated or otherwise unsuitable.

For this indication, competent medicine agencies globally authorize below treatments:

150 mg once a month

For:

Dosage regimens

Subcutaneous, 150 milligrams daclizumab, once monthly.

Detailed description

The recommended dose of daclizumab beta is 150 mg injected subcutaneously once a month.

In case a dose is missed and it is within 2 weeks of the missed dose, patients should be instructed to inject without delay their missed dose and then remain on their original monthly dosing schedule.

If a dose is missed and it is more than 2 weeks from the missed dose, patients should skip the missed dose, wait until their next scheduled dose, and then remain on their original monthly dosing schedule.

Only one dose should be administered at a time to make up for a missed dose.

Dosage considerations

The usual sites for subcutaneous injection include the thigh, abdomen, and back of the upper arm.

Active ingredient

Daclizumab

Daclizumab beta is a humanised IgG1 monoclonal antibody that binds to CD25 (IL-2RĪ±), and prevents IL-2 binding to CD25, resulting in higher levels of IL-2 available for signalling through the intermediate-affinity IL-2 receptor. Key effects of this IL-2 pathway modulation potentially related to the therapeutic effects of daclizumab beta in MS include selective antagonism of activated T-cell responses, and expansion of immunoregulatory CD56bright natural killer (NK) cells, which have been shown to selectively decrease activated T-cells.

Read more about Daclizumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.